Parker Institute for Cancer Immunotherapy Brings the Power of Its Integrated Network to ASCO 2026
The Parker Institute for Cancer Immunotherapy (PICI) will present over 50 research contributions at ASCO 2026, including breakthroughs in glioblastoma, melanoma, and CAR T-cell therapies. The event highlights new data from trials like a bivalent CAR T-cell therapy for recurrent glioblastoma and a personalized neoantigen vaccine for CNS cancers, alongside the announcement of the inaugural Conquer Cancer PICI Endowed Young Investigator Award.
The Parker Institute for Cancer Immunotherapy (PICI) will showcase research from its global network at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29–June 2, 2026. With over 50 oral sessions, posters, and publications, PICI will present advancements in cancer immunotherapy, including new data on glioblastoma, melanoma, prostate, breast, lung, and urothelial cancers. Highlights include updated results from a Phase 1 trial of a bivalent CAR T-cell therapy for recurrent glioblastoma at the University of Pennsylvania, led by Carl June and Donald O’Rourke, and a personalized neoantigen vaccine for glioblastoma at Dana-Farber Cancer Institute, led by Catherine J. Wu and Patrick Ott. PICI will also unveil findings from its RADIOHEAD pan-cancer cohort, featuring multimodal immunoprofiling data using foundation models to predict immunotherapy response and toxicity. This builds on earlier presentations at AACR 2026. Additionally, the institute will announce the first recipient of the Conquer Cancer PICI Endowed Young Investigator Award, recognizing an early-career clinical oncology researcher transitioning from fellowship to faculty. Melanoma research will include Phase 2 results from Stanford’s Allison Betof on relatlimab, nivolumab, and ipilimumab for melanoma brain metastases, as well as OBX-115 TIL therapy with regulatable IL-15 for advanced melanoma. Jedd Wolchok of Weill Cornell Medicine will present updated outcomes from the ECOG-ACRIN EA6174 trial on adjuvant pembrolizumab for Merkel cell carcinoma, while F. Stephen Hodi of Dana-Farber will share a five-year update on nivolumab plus relatlimab in advanced melanoma. The presentations reflect PICI’s collaborative model, translating discoveries into clinical progress. Dr. Karen Knudsen, PICI’s CEO, emphasized the network’s urgency in addressing cancer through coordinated science. The ASCO meeting underscores PICI’s role in advancing immunotherapy strategies across multiple cancer types.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.